CD274 and cancer: These results indicate that HDAC3 inhibits PD-L1 expression in drug-resistant cancer cells in vivo and suggest that HDAC3 activation may be a potential therapeutic approach to reverse the inhibition of T cell-based immunity in drug-resistant tumors.